To determine when 18F-choline PET/CT can truly identify local recurrence of prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
1031 patients from 3 European centers underwent (18)F-choline PET/CT (FCH PET/CT) for recurrent disease; 131 subjects (12.
7%) showed a positive FCH uptake in the prostatic gland or prostatic fossa. Median age was 72 years (range 48-87 years), and the median PSA level at the time of FCH PET/CT scan was 4. 41 ng/mL (0. 22-18. 13 ng/mL). 45 patients (34. 4%) had a Gleason score (GS) >7, and the residual subjects had a GS ≤7. The assessment of true or false-positive FCH PET/CT findings was made by magnetic resonance imaging (n = 34) and/or biopsy in 75/131 cases. A χ (2) test and a Z Kolmogorov-Smirnov test were used to assess the correlation between clinical variables (age, PSA, GS, type of therapy) and FCH PET/CT findings.
FCH PET/CT resulted truly positive (TP) for recurrent disease in the prostatic gland/fossa in 59/75 patients (79%) and falsely positive (FP) in 16 subjects (21%). The median value of PSA at the time of FCH PET/CT scan was higher in TP as compared to FP, although not statistically significant (4. 76 vs. 3. 04 ng/mL p > 0. 05). Similarly, median age, GS categories, and the type of therapy were similar between the two groups (p > 0. 05). However, when matching GS categories and PSA values, we found that the number of patients with TP findings were higher in the case of a PSA >2 ng/mL, independently from the GS (ranging between 74% and 92%). Conversely, FP rate ranged between 50% and 65% in patients with a PSA ≤2 ng/mL, especially in the case of GS ≤7, whereas FP was around 25% in those with a GS >7 and PSA >2 ng/mL.
FCH PET/CT has a limited role in evaluation of prostatic gland/fossa recurrence, due to the physiological biodistribution of the radiopharmaceutical agent. However, in 70-90% of patients with a PSA >2 ng/mL, independently from GS, a focal FCH uptake is compatible with a true local recurrence.
Abdominal imaging. 2015 Oct 01 [Epub ahead of print]
Laura Evangelista, Marino Cimitan, Marina Hodolič, Tanja Baseric, Jure Fettich, Eugenio Borsatti
Radiotherapy and Nuclear Medicine Unit, Veneto Institute of Oncology IOV - IRCCS, Via Gattamelata, 64, 35128, Padua, Italy. laura. evangelista@ioveneto. it. , Nuclear Medicine Unit, IRCCS National Cancer Institute (CRO), Aviano, PN, Italy. , Nuclear Medicine Research Department, IASON, Graz, Austria. , Nuclear Medicine Unit, IRCCS National Cancer Institute (CRO), Aviano, PN, Italy. , Nuclear Medicine Department, University Medical Center Ljubljana, Ljubljana, Slovenia. , Nuclear Medicine Unit, IRCCS National Cancer Institute (CRO), Aviano, PN, Italy.